Limited time offer! 10% off your first blood test order!
Four clinically relevant tumour markers for men. Not a diagnosis — a risk signal and a baseline for annual monitoring.
or 4 interest-free payments of £24.75 with Klarna
A four-marker tumour marker panel for men measuring PSA (prostate), AFP (liver and testicular), CEA (colorectal), and CA 19-9 (pancreatic).
This four-marker cancer screening panel is not a diagnostic test — no blood test alone can diagnose cancer. It is a risk stratification tool that measures the serum tumour markers most clinically relevant to men: PSA for prostate cancer risk, AFP for hepatocellular carcinoma and testicular germ cell tumours, CEA for colorectal cancer monitoring, and CA 19-9 for pancreatic and biliary tract cancer risk. Elevated markers require further clinical investigation, but normal levels provide reassurance as part of a broader preventative health strategy. This panel is most valuable when used longitudinally as part of annual health monitoring, where a rising trend can be detected before a single result would exceed the reference range threshold. All results are reviewed by a GMC-registered physician who provides clear guidance on the significance of each finding and the recommended next steps.
Understand what each marker measures, why it matters, and what the science says — not just a list of numbers.
This panel is designed for adults who want a comprehensive, evidence-based picture of their metabolic health — not a GP referral panel.
Men aged 45 and over wanting an annual cancer risk baseline
Men with a family history of prostate, liver, or colorectal cancer
Men who have had a previous cancer diagnosis and are monitoring for recurrence
Individuals with chronic liver disease or cirrhosis (elevated AFP risk)
Heavy smokers or ex-smokers wanting to monitor CEA as part of broader cancer vigilance
Tumour markers are not cancer-specific. Every marker in this panel can be elevated by benign conditions: PSA by prostatitis and BPH, AFP by liver cirrhosis and hepatitis, CEA by inflammatory bowel disease and smoking, CA 19-9 by pancreatitis and biliary obstruction. A normal panel does not exclude cancer; many cancers do not produce detectable elevations of these specific markers. Conversely, an elevated result requires contextualisation by a clinician with access to symptoms, examination findings, and imaging before any conclusion is drawn. These markers are most valuable when used longitudinally; a rising trend over months is more significant than any single elevated value. This panel is not equivalent to and does not replace NHS cancer screening programmes (bowel cancer screening, lung cancer screening, or specialist surveillance programmes).
From order to physician-reviewed report in as little as three working days.
Venous draw required for AFP and CA 19-9 accuracy.
Abstain from ejaculation and vigorous exercise for 48 hours before collection.
Within 24 hours of receipt.
Physician-reviewed commentary with clear next steps in 3 to 5 working days.
Three options designed to fit your schedule, location, and preference — all producing a laboratory-standard sample.
Adults 18+ in mainland UK. Not suitable if you have had a transfusion in the last 3 months.
Order anytime; kit dispatched within 24 hours Mon–Fri.
Allow 24–48 hours for sample transit on top of lab processing time.
Adults 18+ within 20 miles of a serviced city centre.
Mon–Sun, 06:00–20:00. Next-day booking typical.
Sample reaches the lab within 24 hours of collection.
Adults 16+ with photo ID. Paediatric draws by appointment at selected sites.
Mon–Fri, with Saturday hours at most metropolitan locations.
Samples processed same-day at the receiving clinic.
Every test is processed in a UKAS ISO 15189-accredited laboratory, overseen by GMC-registered physicians, and governed by UK GDPR. No overseas processing, no offshore data.
Follow these guidelines to ensure accurate, reproducible results. Most markers are sensitive to recent food, exercise, and sleep.
Can't find your answer? Our clinical support team is available Monday to Friday, 9am–5pm.
Contact supportNo blood test currently available can definitively diagnose cancer. Tumour markers such as PSA, AFP, CEA, and CA 19-9 are proteins elevated in the blood when certain cancers are present — but they can also be elevated by benign conditions, and many cancers produce no detectable marker elevation at all. These tests are best understood as risk signals and monitoring tools rather than diagnostic tests. An elevated result prompts further investigation through imaging, biopsy, and specialist review; it does not confirm a diagnosis. Similarly, a normal panel does not rule out cancer.
AFP (alpha-fetoprotein) is relevant to men because it is elevated in two cancers with high incidence in younger and middle-aged men: hepatocellular carcinoma (liver cancer) and testicular germ cell tumours (non-seminomas in particular). AFP is also elevated in liver cirrhosis and chronic hepatitis B or C infection regardless of cancer, making it important context when interpreting a raised result. Men with chronic liver disease or a history of viral hepatitis are at meaningfully elevated risk of liver cancer and benefit most from regular AFP monitoring.
CEA can be elevated in several gastrointestinal cancers (colorectal, gastric, pancreatic), lung cancer, breast cancer, and certain ovarian cancers. However, non-malignant causes of elevated CEA include inflammatory bowel disease, liver cirrhosis, chronic lung disease, and, most commonly, cigarette smoking — which can raise CEA two to three times above non-smoker values without cancer. CEA is most useful clinically as a monitoring marker in people who have already been diagnosed with a CEA-secreting cancer, where a rising level after treatment suggests recurrence. As a primary screening tool, its specificity is limited.
A normal CA 19-9 provides some reassurance but cannot exclude pancreatic or biliary cancer. CA 19-9 is not elevated in approximately 10 to 15 percent of individuals due to a genetic variant (Lewis antigen negativity), in whom this marker will always read near zero regardless of disease. Early-stage pancreatic cancer often does not produce elevated CA 19-9 either, meaning the marker’s sensitivity is highest in more advanced disease. CA 19-9 is most informative in monitoring response to treatment in confirmed pancreatic cancer, and as an additional signal when elevated alongside symptoms such as unexplained weight loss, jaundice, or abdominal pain.
For individuals without a cancer history using these markers as preventative surveillance, annual testing is generally recommended. This allows a longitudinal dataset to be built, where a rising trend over several years — even within the reference range — can be detected and investigated before a threshold is crossed. For men in higher-risk groups (family history, chronic liver disease, previous cancer), your specialist or GP may recommend more frequent monitoring. If any marker rises significantly between annual tests, prompt GP review is warranted rather than waiting for the next scheduled test.
